Article Text

other Versions

PDF

Soluble mesothelin in effusions - a useful tool for the diagnosis of malignant mesothelioma
  1. Jenette Creaney (creaneyj{at}cyllene.uwa.edu.au)
  1. Australian National Research Centre for Asbestos Related Diseases, Australia
    1. Deborah Yeoman (dyeoman{at}cyllene.uwa.edu.au)
    1. Australian National Research Centre for Asbestos Related Diseases, Australia
      1. leanne Naumoff (leannen{at}cyllene.uwa.edu.au)
      1. Australian National Research Centre for Asbestos Related Diseases, Australia
        1. Michelle Hof (mchof{at}cyllene.uwa.edu.au)
        1. Australian National Research Centre for Asbestos Related Diseases, Australia
          1. Amanda Segal (amanda.segal{at}health.wa.gov.au)
          1. PathWest Laboratories, Australia
            1. William Arthur Musk (bill.musk{at}health.wa.gov.au)
            1. Australian National Research Centre for Asbestos Related Diseases, Australia
              1. Nick De Klerk (nickdk{at}ichr.uwa.edu.au)
              1. Australian National Research Centre for Asbestos Related Diseases, Australia
                1. Nora Horick (nhorick{at}partners.org)
                1. Massachusetts General Hospital, United States
                  1. Steven J Skates (sskates{at}partners.org)
                  1. Massachusetts General Hospital, United States
                    1. Bruce W. S. Robinson (bwsrobin{at}cyllene.uwa.edu.au)
                    1. Australian National Research Centre for Asbestos Related Diseases, Australia

                      Abstract

                      Background Diagnosis of malignant mesothelioma is frequently difficult, the most common differential diagnosis being reactive pleural conditions and metastatic adenocarcinoma. Soluble mesothelin levels in serum have recently been shown to be highly specific and moderately sensitive for mesothelioma. So as most mesothelioma patients present with exudative effusions of either the pleura or peritoneum, we sought to determine if levels of mesothelin were elevated in these fluids and if any elevations could help distinguish mesothelioma from other causes of exudative effusion.

                      Patients and Methods Pleural fluid was collected from 192 patients who presented to respiratory clinics; 52 patients with malignant mesothelioma, 56 with non- mesotheliomatous malignancies and 84 with effusions of non-neoplastic origin. Peritoneal fluid was collected from 42 patients; 7 with mesothelioma, 14 with non- mesotheliomatous malignancies and 21 benign effusions. Mesothelin levels were determined on effusion and serum samples by ELISA.

                      Results Mesothelin was statistically significantly higher in effusions of patients with mesothelioma; with a specificity of 98% the assay had a sensitivity of 67% comparing mesothelioma patients to patients with effusions of non-neoplastic origin. In 7 out of 10 cases mesothelin was elevated in the effusion collected 3 weeks to 10 months before the diagnosis of mesothelioma was made, and in 4 out of 8 of these cases mesothelin was elevated in the effusion but not in the serum.

                      Conclusions Measurement of mesothelin concentrations in the pleural and/or peritoneal effusion of patients may aid in the differential diagnosis of mesothelioma in patients presenting with effusions.

                      • diagnostics
                      • effusion
                      • mesothelin
                      • mesothelioma
                      • tumour marker

                      Statistics from Altmetric.com

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                      Linked Articles